Loading…
Nautilus Biotechnology, Inc. is projected to rise to $3.28 by 2027, a +28% move from its current price of $2.56. NAUT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $2.45 | $2.56 | $2.68 | +0.11% |
| May 30 | $2.41 | $2.57 | $2.74 | +0.22% |
| May 31 | $2.37 | $2.57 | $2.78 | +0.33% |
| Jun 1 | $2.35 | $2.57 | $2.82 | +0.45% |
| Jun 2 | $2.32 | $2.57 | $2.85 | +0.56% |
| Jun 3 | $2.30 | $2.58 | $2.88 | +0.67% |
| Jun 4 | $2.29 | $2.58 | $2.91 | +0.78% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.29 | $2.58 | $2.91 | +0.78% |
| Week 2 | $2.19 | $2.60 | $3.08 | +1.57% |
| Week 3 | $2.13 | $2.62 | $3.23 | +2.37% |
| Week 4 | $2.07 | $2.64 | $3.36 | +3.17% |
| Week 5 | $2.03 | $2.66 | $3.49 | +3.98% |
| Week 6 | $2.00 | $2.68 | $3.61 | +4.79% |
| Week 7 | $1.96 | $2.70 | $3.72 | +5.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nautilus Biotechnology, Inc. is a development stage life sciences company focused on quantifying and unlocking the complexity of the proteome in the United States. It develops the Nautilus Voyager Platform, an end-to-end solution comprising instruments, reagents, consumables, and software analysis, and offers the Nautilus Voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
The company maintains research collaboration agreements with Genentech, Buck Institute, Allen Institute, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation. Nautilus Biotechnology, Inc.
was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc. (NAUT) is trading at $2.54 per share with a market capitalization of $322.78M. Its rank is 3454 in market cap terms. The stock is positioned within the healthcare sector as a development stage life sciences company pursuing its proteome-quantification platform.
The near-term outlook begins neutral in 2026, with an average price of $2.54, and progresses toward bullish territory in later years. The forecast shows ongoing upside through 2030, 2040, and 2050, with the 2050 average price projected at $18.25 and a headline max of $41.97, corresponding to a substantial long-run upside potential.
A major floor 28.4% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
The nearest ceiling, 27.0% above — a clean break opens room to run.
A major ceiling 54.3% above — clearing it would confirm fresh momentum.
Key NAUT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NAUT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.49 | Buy | $2.51 | Buy |
| MA 10 | $2.53 | Buy | $2.55 | Buy |
| MA 20 | $2.67 | Sell | $2.64 | Sell |
| MA 50 | $2.94 | Sell | $2.72 | Sell |
| MA 100 | $2.60 | Sell | $2.55 | Buy |
| MA 200 | $1.95 | Buy | $2.20 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.86 | Neutral |
| Stoch RSI (14) | 48.69 | Neutral |
| CCI (20) | -37.53 | Neutral |
| Williams %R (14) | -69.70 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -4.48 | Sell |
| Bollinger %B (20,2) | 0.38 | Neutral |
| Stochastic %K (14) | 30.30 | Neutral |
| TRIX (15) | -0.52 | Sell |
| Awesome (5,34) | -0.27 | Sell |
| Ultimate (7,14,28) | 48.07 | Neutral |
| Momentum (10) | -0.37 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 2.52 | Buy |
| ADX (14) | 13.35 | Neutral |
| ATR (14) | 0.11 | Info |
The near-term technical picture includes bullish sentiment but modest momentum, with RSI14 at 40. Price action is between the SMA200 at $1.94 and the SMA50 at $2.94. Support is listed at $2.36 and resistance at $3.25. The 30-day trading range spans from $1.87 to $3.45, highlighting a window of variation around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.83 | $2.56 | $3.78 | 0% | Neutral | |
| $2.43 | $3.28 | $4.77 | +28% | Bullish | |
| $2.32 | $3.28 | $5.04 | +28% | Bullish | |
| $2.48 | $3.66 | $5.87 | +43% | Bullish | |
| $2.61 | $4.00 | $6.64 | +56% | Bullish | |
| $2.81 | $4.47 | $7.65 | +75% | Bullish | |
| $3.82 | $6.27 | $11.03 | +145% | Bullish | |
| $4.31 | $7.32 | $13.18 | +186% | Bullish | |
| $4.30 | $7.52 | $13.86 | +194% | Bullish | |
| $4.13 | $7.44 | $14.00 | +191% | Bullish | |
| $6.77 | $14.07 | $28.84 | +450% | Bullish | |
| $9.52 | $21.16 | $48.67 | +727% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.83 | $2.56 | $3.04 | +0.00% |
| June 2026 | $2.30 | $2.74 | $3.38 | +7.17% |
| July 2026 | $2.34 | $2.83 | $3.56 | +3.29% |
| August 2026 | $2.29 | $2.80 | $3.58 | -1.19% |
| September 2026 | $2.34 | $2.89 | $3.75 | +3.25% |
| October 2026 | $2.43 | $3.02 | $3.96 | +4.45% |
| November 2026 | $2.34 | $2.94 | $3.90 | -2.73% |
| December 2026 | $2.23 | $2.82 | $3.78 | -4.05% |
Click any year to see its month-by-month NAUT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NAUT is projected to trade between $1.83 and $3.78, averaging $2.56 — a potential gain of 0% from today's $2.56. A consolidation phase looks the most probable path here.
Nautilus Biotechnology, Inc.'s 2027 outlook centres on $3.28, within a $2.43 to $4.77 range. That is up +28% on the projected 2026 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2028, NAUT could reach as high as $5.04, with a base case around $3.28 and support toward $2.32 — roughly +28% from $2.56. Buyers look set to stay in control over this stretch.
Expect NAUT to range from $2.48 to $5.87 through 2029. The $3.66 average target implies a +43% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The NAUT price prediction for 2030 points to an average of $4.00 (low $2.61, high $6.64) — a potential gain of +56% on today's $2.56. Buyers look set to stay in control over this stretch.
In 2031, NAUT is projected to trade between $2.81 and $7.65, averaging $4.47 — a potential gain of +75% from today's $2.56. That is up +12% on the projected 2030 average. Momentum favours further upside here.
Nautilus Biotechnology, Inc.'s 2032 outlook centres on $6.27, within a $3.82 to $11.03 range. That is up +40% on the projected 2031 average. That marks a +145% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, NAUT could reach as high as $13.18, with a base case around $7.32 and support toward $4.31 — roughly +186% from $2.56. Momentum favours further upside here.
Expect NAUT to range from $4.30 to $13.86 through 2034. The $7.52 average target implies a +194% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The NAUT price prediction for 2035 points to an average of $7.44 (low $4.13, high $14.00) — a potential gain of +191% on today's $2.56. Momentum favours further upside here.
In 2040, NAUT is projected to trade between $6.77 and $28.84, averaging $14.07 — a potential gain of +450% from today's $2.56. That is up +89% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Nautilus Biotechnology, Inc.'s 2050 outlook centres on $21.16, within a $9.52 to $48.67 range. That is up +50% on the projected 2040 average. That marks a +727% change versus current levels. Momentum favours further upside here.
Investing $1,000 in NAUT today (≈ 390.625 NAUT) could be worth
$8,265.76
+$7,265.76 (+727%) by 2050 · US Dollar
Based on the average projected NAUT price of $21.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NAUTwould be worth at today's price.
$1,000 invested in NAUT on May 27, 2025 (≈ 1,293.661058 NAUT) would be worth
$3,311.77
+$2,311.77 (+231.2%) today · 3.31× · US Dollar
Based on a NAUT entry price of $0.773 vs. today's $2.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.38 | $1,075.63 | +7.6% |
| 1 month ago | $2.57 | $996.11 | -0.4% |
| 3 months ago | $2.42 | $1,057.85 | +5.8% |
| 6 months ago | $2.25 | $1,137.78 | +13.8% |
| 1 year ago | $0.773 | $3,311.77 | +231.2% |
| All time (5.0y) ago | $10.2 | $250.98 | -74.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NAUT forecast.
Our base-case forecast reaches $5.10 around 2032.
Implied market cap at $5.10: $648.1M
The multi-year forecast shows a rising trajectory for Nautilus, with average prices climbing from $2.54 in 2026 to $18.25 in 2050 and notable upside in between. For 2027 the average is $3.23 with a 27.1% ROI, rising to $3.77 in 2030 with 48.5%, and $5.79 in 2032 with 127.8%, then higher to $12.36 in 2040 with 386.7% ROI and finally $18.25 in 2050 with 618.4% ROI. Max values extend to $10.22 in 2032 and to $41.97 in 2050, with a long-run bullish sentiment across the horizon.
These are estimates, not guarantees, and actual results may vary. The forecast depicts a wide range of outcomes, reflecting ongoing uncertainty and the potential for substantial upside alongside downside risk.
Tap a question to reveal the answer.
2030 average price is $3.77; min $2.44; max $6.29; ROI 48.5%.
Forecasts show bullish sentiment in multiple years, with 2027 avg $3.23 (ROI 27.1%), 2040 avg $12.36 (ROI 386.7%), and 2050 avg $18.25 (ROI 618.4%). These are estimates and not guarantees.
2032 max is $10.22, so the forecast allows a level around $10 in that year.
Current price is $2.54 per share, with a market capitalization of $322.78M.
2050 average price is $18.25 with a min of $8.21 and a max of $41.97; ROI 618.4%; sentiment BULLISH.
Nautilus Biotechnology, Inc. Community Discussion
0Share your Nautilus Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.